JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.63 Billion KRW | -9.93% |
| 2022 | 2.92 Billion KRW | 28.31% |
| 2021 | 2.27 Billion KRW | 140.79% |
| 2020 | -5.58 Billion KRW | 47.96% |
| 2019 | -10.73 Billion KRW | -135.89% |
| 2018 | -4.55 Billion KRW | -13.63% |
| 2017 | -4 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.15 Billion KRW | 24.44% |
| 2024 Q1 | 1.72 Billion KRW | 1780.86% |
| 2023 Q1 | 1.1 Billion KRW | 279.67% |
| 2023 Q3 | 515.15 Million KRW | -44.15% |
| 2023 Q2 | 922.44 Million KRW | -16.45% |
| 2023 FY | 2.63 Billion KRW | -9.93% |
| 2023 Q4 | 91.91 Million KRW | -82.16% |
| 2022 Q2 | 1.05 Billion KRW | 111.03% |
| 2022 Q1 | 502.11 Million KRW | -70.76% |
| 2022 Q3 | 1.07 Billion KRW | 1.13% |
| 2022 FY | 2.92 Billion KRW | 28.31% |
| 2022 Q4 | 290.8 Million KRW | -72.86% |
| 2021 Q3 | -1.21 Billion KRW | -248.67% |
| 2021 Q4 | 1.71 Billion KRW | 240.96% |
| 2021 Q1 | 960.43 Million KRW | -30.49% |
| 2021 FY | 2.27 Billion KRW | 140.79% |
| 2021 Q2 | 819.45 Million KRW | -14.68% |
| 2020 Q3 | -1.94 Billion KRW | 13.25% |
| 2020 Q1 | -2.77 Billion KRW | 24.33% |
| 2020 FY | -5.58 Billion KRW | 47.96% |
| 2020 Q4 | 1.38 Billion KRW | 170.95% |
| 2020 Q2 | -2.24 Billion KRW | 19.12% |
| 2019 Q3 | -2.75 Billion KRW | 0.0% |
| 2019 FY | -10.73 Billion KRW | -135.89% |
| 2019 Q4 | -3.66 Billion KRW | -33.08% |
| 2019 Q1 | -2.67 Billion KRW | 0.0% |
| 2018 Q1 | -548.52 Million KRW | 0.0% |
| 2018 FY | -4.55 Billion KRW | -13.63% |
| 2017 FY | -4 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 102.106% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | 180.173% |
| BINEX Co., Ltd. | 1.04 Billion KRW | -152.685% |
| Bioneer Corporation | 791.75 Million KRW | -232.634% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 151.906% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 110.48% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 108.52% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 107.472% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 127.943% |
| Medy-Tox Inc. | 17.32 Billion KRW | 84.796% |
| Peptron, Inc. | -15.6 Billion KRW | 116.879% |
| Amicogen, Inc. | 2.05 Billion KRW | -28.087% |
| Genexine, Inc. | -41.24 Billion KRW | 106.386% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 130.271% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 103.259% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 127.048% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 97.388% |
| SillaJen, Inc. | -21.34 Billion KRW | 112.338% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 114.482% |
| Genomictree Inc. | -17.3 Billion KRW | 115.22% |
| MedPacto, Inc. | -28.75 Billion KRW | 109.16% |
| D&D Pharmatech | -13.48 Billion KRW | 119.528% |
| EASY BIO,Inc. | 20.63 Billion KRW | 87.235% |
| GI Innovation, Inc. | -55.6 Billion KRW | 104.736% |